← MacroGenics, Inc. (MGNX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MacroGenics, Inc. (MGNX)
Pharmaceutical Preparations · market cap $251M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
7
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
MacroGenics (MGNX) is a ~$290M market-cap clinical-stage biopharma with 341 employees and a diversified but capital-intensive pipeline spanning oncology and autoimmune disease. The company reported $150M in 2025 revenue against a $75M net loss, but holds only ~$66.5M in cash — implying roughly 5.6 months of runway — making near-term financing a structural overhang. The lead clinical catalyst is lorigerlimab in androgen-independent prostate cancer, with Phase 2 readouts estimated in September 2026 and February 2027.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-02-15 (est.)Phase 2 · lorigerlimabimp 7/10
- 2027-07-15 (est.)Phase 2 · lorigerlimabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Margetuximab 10 mg/kg | Phase 2 | Gastric Cancer |
| vobramitamab duocarmazine 2.0 mg (Arm A) | Phase 2 | Castration-Resistant Prostatic Cancer |
| lorigerlimab | Phase 2 | Androgen-Independent Prostatic Cancer |
| Teplizumab | Phase 3 | Type 1 Diabetes Mellitus |
| Margetuximab | Phase 3 | HER-2 Positive Breast Cancer |
| Retifanlimab | Phase 3 | Gastric Cancer |
| MGD007 + MGA012 | Phase 2 | Colorectal Cancer Metastatic |
Price & technical context
3-month
-23.6%
6-month
+24.1%
12-month
+114.3%
52-wk range
$1.33–$4.86
vs 50-day MA
-10.2%
vs 200-day MA
+10.6%
Realized vol
79.9%
Max drawdown
-76.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MGNX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.